Cost Effectiveness of N-terminal Pro B-type Natriuretic Peptide for Evaluation and Management of People With Type 2 Diabetes in the Perspective of Brazilian Private Healthcare System
NT-proBNP-based strategy offers improved health outcomes and cost savings by reducing the long-term HF burden. Although the short-term budget impact indicates an initial net investment, the full clinical benefit of cardioprotective treatment is observed in a longer time horizon.
Authors
- Guilherme Lemos
- Rodica Pop-Busui
- Paul Neveux
- Marcus Vinicius Bolivar Malachias
- James L. Januzzi
Institutions
- Roche (Switzerland) (CH)
- Oregon Health & Science University (US)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Baim Institute for Clinical Research (US)
- Roth and Rau (Germany) (DE)
Publication Details
- Journal
- Value in Health Regional Issues
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1016/j.vhri.2026.101588
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00